Commentary Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/immunology.2.027

A novel therapeutic strategy for antifibrotic based on a new gene NS5ATP9

  • 1Peking University Ditan Teaching Hospital, Beijing 100015, China
  • 2Institiute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University/Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, China
  • 3Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing 100191, China
+ Affiliations - Affiliations

Corresponding Author

Jun Cheng, chengj0817@sina.cn

Received Date: February 12, 2020

Accepted Date: April 07, 2020


In this article, we introduced a screening of anti-fibrotic drugs focused on new genes. More precisely, we screened and cloned 127 new genes, reporting on a potential target gene and two promising drugs for fibrosis. Among 127 genes, hepatitis C virus nonstructural protein 5A transactivated protein 9 (NS5ATP9), which expression is significantly upregulated by tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide fumarate (TAF), suppresses hepatic stellate cells (HSCs) and HFL1 cells (lung fibroblasts) activation. Therefore, we reported NS5ATP9 as a potential therapeutic target, and TDF/TAF as a new promising therapeutic strategy in fibrosis. These results elucidate mechanisms of disease and translate molecular techniques into clinical treatment.


NS5ATP9; gene; anti-fibrotic drugs; TDF; TAF; hepatocellular carcinoma; hepatitis C virus

Author Information X